Repligen Co. (NASDAQ:RGEN – Get Rating) insider Christine Gebski sold 3,357 shares of the firm’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $243.01, for a total value of $815,784.57. Following the completion of the sale, the insider now owns 30,735 shares of the company’s stock, valued at $7,468,912.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Repligen Trading Up 1.2 %
Shares of RGEN opened at $246.27 on Friday. Repligen Co. has a 1 year low of $137.21 and a 1 year high of $327.32. The stock has a market cap of $13.40 billion, a P/E ratio of 88.91 and a beta of 1.07. The stock’s 50-day moving average price is $175.20 and its two-hundred day moving average price is $174.08.
Repligen (NASDAQ:RGEN – Get Rating) last released its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.19. The company had revenue of $207.63 million for the quarter, compared to analyst estimates of $189.06 million. Repligen had a return on equity of 11.18% and a net margin of 20.47%. Repligen’s revenue was up 27.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.79 earnings per share. As a group, equities analysts forecast that Repligen Co. will post 3.21 EPS for the current year.
Institutional Investors Weigh In On Repligen
Analyst Ratings Changes
Several equities analysts recently issued reports on RGEN shares. Craig Hallum decreased their price target on Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. Stephens raised their price target on Repligen from $220.00 to $275.00 and gave the company an “overweight” rating in a report on Wednesday. KeyCorp raised their price target on Repligen from $245.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday. SVB Leerink raised their price target on Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, UBS Group started coverage on Repligen in a report on Wednesday, July 20th. They issued a “buy” rating and a $213.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $276.00.
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.